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ABSTRACT
Disease-causing variants in human genes usually
lead to phenotypes specific to only a few tissues.
Here, we present a method for predicting tissue
specificity based on quantitative deregulation of
protein complexes. The underlying assumption is
that the degree of coordinated expression among
proteins in a complex within a given tissue may
pinpoint tissues that will be affected by a mutation
in the complex and coordinated expression may
reveal the complex to be active in the tissue.
We identified known disease genes and their
protein complex partners in a high-quality human
interactome. Each susceptibility gene’s tissue
involvement was ranked based on coordinated
expression with its interaction partners in a non-
disease global map of human tissue-specific ex-
pression. The approach demonstrated high overall
area under the curve (0.78) and was very success-
fully benchmarked against a random model and an
approach not using protein complexes. This was
illustrated by correct tissue predictions for three
case studies on leptin, insulin-like-growth-factor 2
and the inhibitor of NF-jB kinase subunit gamma
that show high concordant expression in biologic-
ally relevant tissues. Our method identifies novel
gene-phenotype associations in human diseases
and predicts the tissues where associated pheno-
typic effects may arise.
INTRODUCTION
Although most genes and their protein products function
as modules within biological networks, their tissue-speciﬁc
functions in metazoans have largely been analysed from
the perspective of individual disease genes. Previous
studies have, for example, quantiﬁed the expression of
>6000 proteins in individual tissues (1), and although
these data typically target individual proteins, they can
be linked with gene expression data to begin to analyse
the disease-speciﬁc functions of entire complexes.
Likewise, it is clear that phenotypes arising from muta-
tions in human genes are usually highly speciﬁc to a
limited number of tissues (2,3). A more integrative and
systems-level approach to the problem of assigning
tissue speciﬁcity to groups of disease-linked genes and
proteins is therefore in order.
Recently, a strategy was developed for systematically
correlating the manifestations of diseases with expression
patterns of genes and protein complexes across human
tissues (1). This established a signiﬁcant tendency for
disease genes to be over-expressed in tissues where
defects cause pathology, even under non-disease condi-
tions. This analysis was based on expression data from
the GNF tissue atlas (4), delivering tissue-speciﬁc expres-
sion data for 73 normal tissues. More than 1000 diseases
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derived from Online Mendelian Inheritance in Man
(OMIM) were analysed by integrating expression data
with disease protein complexes. A second recent study
integrated interaction and expression data to analyse the
interplay between protein expression and physical inter-
actions in human tissues (5). This revealed that most
tissue-speciﬁc proteins normally interact with core
cellular components, and that most universally expressed
or ‘housekeeping’ proteins have tissue-speciﬁc protein
interactions. Finally, a third examination of the dynamic
structure of the interactome found changes in its organiza-
tion predictive of breast cancer outcome (6). Speciﬁcally,
intermodular hub proteins were found with low correlation
with interaction partners and tissue-speciﬁc expression, in
contrast with intramodular hub proteins with correlated
patterns of co-expression across tissues. These were based
on average Pearson correlation coefﬁcients (PCCs) of co-
expression of a hub protein and its partners to quantify
context-speciﬁc interactions (that is, interacting proteins
not consistently co-expressed) or constitutive (interacting
proteins frequently co-expressed).
Considering these three studies together, Bossi and
Lehner (2009) analysed the interplay between protein ex-
pression and physical interactions in humans, but without
linking these to diseases (5). In contrast, Lage et al. (2008)
correlated diseases with normal expression patterns of
protein complexes across human tissues, but did not in-
vestigate protein complex co-expression (1). Finally,
Taylor et al. (2009) identiﬁed changes in the organization
of the interactome based on a co-expression measure and
used these changes to predict breast cancer outcome (6).
This work combines the strengths of these previous studies
and builds on them to determine the tissue and disease
speciﬁcity of a broad set of human protein complexes in
a novel manner.
Here, we introduce TissueRanker, a predictive method
for disease/tissue associations based on a co-expression
measure of transcripts within human protein complexes,
leveraging a recently published global map of human
gene expression data (7). This larger set of human expres-
sion data allowed the analysis of disease-linked pro-
tein complexes speciﬁc to many tissues. In particular,
TissueRanker uses the assumption that a protein
complex in which the hub protein is conﬁrmed to be
involved in a certain disease should be well coordinated
in expression in the normal tissue where mutations cause a
disease phenotype. Accordingly, coordinated expression
of disease genes with their protein interaction partners
proved to provide direct insight into the tissues they
affected in the disease. We demonstrated this using
a benchmark dataset consisting of 248 gene-disease–
tissue associations, resulting in accurate performance of
area under the curve (AUC=0.78) over all tissues
(Figure 2B). This tissue ranking based on coordinated
protein complex expression was more accurate than tests
using individual proteins (AUC=0.59), or a random
model (AUC=0.52). Three case studies were also illus-
trative: the leptin (LEP) gene recently linked to neuro-
degenerative disorders (8,9), which showed concordant
expression in distinct brain tissues; the insulin-like
growth factor 2 (IGF2), with concordant expression in
smooth muscle and brain tissue, highlighting its biological
roles in muscle differentiation and cerebellum morphology
as found in previous studies (10,11); and the inhibitor of
NF-B kinase subunit gamma (IKK-), found to be co-
expressed in prostate tissue as supported by previous
ﬁndings (12,13).
MATERIALS AND METHODS
The key elements in TissueRanker are to compute a
(normalized) coordinated expression value for each
protein complex in each tissue by calculating the average
co-expression PCC between a hub protein and its inter-
action partners in a provided underlying protein network.
Tissues are subsequently ranked for each protein complex
by their coordinated expression values (Figure 1).
According to our hypothesis, the tissue with the highest
coordinated expression value will be the one where
deregulation of the hub gene most likely would cause a
detrimental phenotype.
Network of protein complexes
Protein–protein interaction networks are regarded as a
reliable type of molecular interactomes as shown in (14).
Protein–protein interactions give rise to a plethora of
higher-order cellular structures (in this work referred
to as protein complexes) that can act as molecular
machines, such as the RNA polymerase 2 complex, form
dynamic signaling networks, such as the JAK-STAT
signaling pathway, or assemble into relatively rigid
cellular structures, such as the cytoskeleton. To construct
a set of high-conﬁdence protein complexes, we used the
InWeb v4.1 protein–protein interaction database that
currently consists of 13 000 proteins and 158 201 protein
interactions for extraction of 9889 protein complexes
(14). We constructed protein–protein interaction subnet-
works (referred to as protein complexes hereafter) by
mapping the directly interacting proteins to a given
hub protein (for all proteins having at least ﬁve
interactor proteins), which resulted in 3590 protein
complexes. A degree cutoff of >5 has been suggested to
represent the highest 15% of the degree distribution of
hub proteins (6). Protein can be present in several
protein complexes.
Global map of human gene expression data
We used a global map of human gene expression (7) con-
taining 5372 samples and representing 128 different tissues
in four different cell types (normal, disease, neoplasm and
cell line). Among the tissues, 64 with normal status were
available with up to 416 samples per tissue. Considering
only experiments with at least ﬁve replicates (6) and
excluding tissues that were not suitable for our analysis
(such as lung tissue from transplants, current and former
smokers, as well as a human universal reference), we
ended up using expression data from 36 different tissues
(Supplementary Table S1).
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Coordinated expression in protein complexes
For each hub protein, the average PCC of co-expression
for each interaction and the hub was assessed using an
algorithm similar to what was previously described (6,
15). Let a protein complex C consist of a hub protein H
and its interactor I1, . . . ,In, n  5. Let XtIi be the expression
data of interactor Ii of hub H for a speciﬁc tissue t, and let
XtH be the expression data for hub H for a speciﬁc tissue t.
The PCC of co-expression, PCCtIi,H, between a hub H and
its interactor Ii in a tissue t across all samples j can be
computed by:
PCCtIi,H ¼
Pn
j¼1 ðXtIi ð jÞ  XtIiÞðXtHð jÞ  XtHÞ
ðn 1ÞstIstH
ð1Þ
To compute the correlation between a hub protein H
and all its interactors I1, . . . ,In in complex C, the co-ex-
pression PCCtIi,H for each hub-interactor pair is computed.
Taking the average of these single co-expression values
results in the ‘coordinated expression’ of complex C for
a speciﬁc tissue t:
CEtC ¼
Pn
i¼1 PCC
t
Ii,H
n
ð2Þ
For each of the 3590 protein complexes, we computed
the degree of coordinated expression of members in each
complex across all tissues. This resulted in a 3590 36
coordinated expression matrix containing the coordinated
expression for each protein complex in the underlying
InWeb network across all 36 tissues.
Statistical inference and tissue ranking
The number of samples highly varied among the tissues
(Supplementary Table S1). To alleviate the potential bias,
we have ﬁrst applied the Fisher transformation to obtain
approximately normal distribution (see Equation 3),
and then standardized by computing standard scores
(z-values):
ztC ¼
1
2
ln
1+CEtC
1 CEtC
ð3Þ
z scoretC ¼
ztC  t
t
ð4Þ
To determine in which tissue a given protein complex
is most coordinated, we ranked the coordinated expres-
sion values of all tissues in decreasing order. We hypothe-
size that tissues with high coordinated expression values
are the ones where genetic variation (or aberrant protein
modiﬁcation) in the corresponding hub protein most likely
will cause detrimental downstream phenotypes.
Gold standard for validation
To benchmark our approach, we compiled a gold
standard set of gene–disease relationships. This was
generated based on the disease–tissue association matrix
deﬁned in (1) combined with known disease–gene associ-
ations from OMIM (version February 2010) by assigning
diseases from OMIM and corresponding tissues from (1)
to each protein and its complex. Integration of these
two datasets resulted in a gold standard matrix compiling
248 genes associated with 36 non-disease tissues and 165
distinct OMIM diseases (Supplementary Table S3). These
relationships comprised our literature-based reference
associating Mendelian disease genes with tissues and
were used to benchmark performance of tissue predictions
identiﬁed by TissueRanker.
Deﬁning tissue categories for validation
For comparison of tissues, we grouped the 36 tissues from
our coordinated expression matrix (excluding bone tissue,
Figure 1. The key steps in the approach: First, for each candidate hub protein, we identify interaction partners from a human interactome and
associate expression levels to each partner. Second, we compute for each protein complex its coordinated expression in all tissues by calculating the
average co-expression (PCC) between the hub protein and its interaction partners. Third, we rank for each complex the tissues by their coordinated
expression values (PCC scores). According to the underlying hypothesis, the tissue with the highest coordinated expression value will be the one
where mutations would most likely cause a disease phenotype.
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as it was not present in the gold standard) and the 51
tissues from the gold standard into 14 tissue categories
(Supplementary Table S2). Alternatively, our analysis
would have been restricted to fewer tissues, namely
those that are present in both datasets, thereby missing
several subtissues.
These tissue groups are hence referred to as tissue
categories. Most tissue categories comprise several
tissues (e.g. the tissue category ‘heart’ contains ‘atrial
myocardium’ and ‘cardiac ventricle’ in our approach,
whereas it contains the tissues ‘cardiac myocytes’ and
‘atrioventricular node’ in the gold standard). To keep con-
sistency and facilitate the tissue comparison, we refer to
the tissue category whenever referring to a speciﬁc (sub-)
tissue of a tissue (e.g. instead of using the speciﬁc tissue
‘cardiac myocytes’, we will term it by its category ‘heart’).
Validation
To validate our predictions, we used the values from the
pre-computed ‘coordinated expression matrix’ (as
described earlier) for the 248 protein complex–disease as-
sociations across all tissues. We then ranked the tissues for
each of these gene products according to their coordinated
expression. We compared these predicted ranks with the
ranks as deﬁned by the gold standard. For some protein
complexes, multiple distinct diseases were available [e.g.
ATM is associated both with Breast Cancer, OMIM
#114480 (16), and with Ataxia, OMIM #208900 (17)].
Because the gold standard ranks tissues according to
their associations to diseases based on literature, and
TissueRanker ranks tissues of protein complexes according
to their coordinated expression in tissues, the gold standard
produces distinct tissue rankings for the same protein as
long as the disease is different. TissueRanker, however,
produces a unique tissue ranking per protein complex, in-
dependent of its known disease association. Next, we used
receiver operating statistics curves and AUC values to
quantify sensitivity and speciﬁcity values of our predicted
ranking compared with the gold standard ranking. This
was achieved by turning the rankers into binary classiﬁers
applying a threshold on the ranking that created a point in
the receiver operating statistics curves space.
In addition to this performance assessment comparing
the global TissueRanker predictions with the gold
standard, we also reported the overlap of the top three
predicted with the top three gold standard tissues:
rGS
m
\ rPred
m (for m=1,..,3 if top three tissues are
considered).
To assess whether TissueRanker produced more
accurate tissue predictions than single-protein expression
analysis, we generated a tissue ranking for each protein in
our benchmark by computing the test statistic of an
unpaired t-test between the expression values of one
tissue and the expression values of the remaining tissues.
The resulting tissue-speciﬁc test statistics for all tissues and
all benchmark proteins were compared against the gold
standard ranking in the same way as above.
Finally, to show that TissueRanker performs better
than random expectations, we repeated our entire
approach based on randomized gene expression data.
Randomization was accomplished by shufﬂing genes
tissue-speciﬁc expression values for each tissue 100 times,
followed by recomputing coordinated expression for each
protein complex.
Tissue distance matrices
Based on the genome-wide expression data, we computed
the pairwise correlation (PCC) between tissues, producing
tissue distance matrices containing all the pairwise dis-
tances for a given set of tissues. Supplementary Figure
S1 illustrates the distance matrices as heatmaps of all
the 36 tissues from our study and the 14 benchmark
tissue categories, respectively. From the tissue distance
matrices, we applied the neighbor-joining algorithm (18)
to generate unrooted distance trees displaying tissue-
relationships in the space of gene expression levels.
RESULTS
We used 3590 protein complexes and a recently published
global map of human gene expression data in
TissueRanker to predict the tissue speciﬁcity of disease
phenotypes arising from defects in these complexes. The
approach was benchmarked using a gold standard set con-
taining 248 unique human protein–disease associations
(see ‘Materials and Methods’ section), resulting in an
overall performance of an AUC of 0.78 across all tissues
(Figure 2B). Although it is well established that genome-
wide expression proﬁles can be used to quantify inter-
tissue relationships (1,7), this method makes it possible
to also determine the tissue speciﬁcity of much smaller
transcriptional units, such as individual pathways or
protein complexes. Details of the method, its validation
and several biological examples are as follows.
Global performance of TissueRanker across human tissues
To assess TissueRanker’s accuracy of prediction within
individual tissue contexts, we benchmarked our
approach against a literature-derived gold standard set,
achieving AUC values >0.8 for most tissues
(Figure 2A). Average performance across all individual
tissues was AUC=0.75, but as expected, this varied by
tissue type. The best performing tissues (i.e. most accur-
ately predicted disease associations) were adipose (0.94),
placental (0.91), prostate (0.89) and thyroid (0.83),
whereas the worst tissues were blood (0.54), lymphatic
system (0.58), brain (0.61) and ovary (0.69).
The broadest distribution of ranks was observed in
blood (see Figure 3), possibly owing to the large number
of heterogeneous samples (437) included in the ‘tissue’
(see Supplementary Table S1), whereas the smallest distri-
bution can be observed in the well-performing tis-
sues, adipose, placenta and prostate (Figure 2A,
Supplementary Figure S3). Thus, tissues that were more
difﬁcult to predict were characterized by a high diversity
of included cell types (e.g. blood, lymphatic system or
brain tissue), whereas well-characterized tissues were
typically more homogeneous.
We next compared tissue predictions from our
method with the gold standard by identifying the top
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Figure 2. Receiver operating statistics curve (ROC) and corresponding AUC showing the performance of the tissue ranking in comparison with the
gold standard for all 248 protein–disease associations from the benchmark (Supplementary Table S3). Curves are shown for each tissue separately in
(A) and in total in (B).
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Figure 3. Distribution of the tissue ranks showing the performance of the tissue ranking in comparison with the gold standard for all 248 protein-
disease associations from our benchmark (Supplementary Table S3) for each tissue separately. Note that only either one or two tissues were ranked
in the top for eye and uterus, respectively. Therefore, no boxplots are shown here for these two tissues.
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three ranked tissues in each (see ‘Materials and Methods’
section). The benchmark set includes several proteins (40
of 243, 17%) that occur multiple times, as they are
involved in multiple diseases [e.g. lamin A/C (LMNA)
is associated with all the three diseases, cardiomyopathy
(19), Charcot-Marie-Tooth disease (20) and muscular dys-
trophy (21)]; additionally, some diseases are also
associated with multiple proteins [e.g. diabetes is
associated with 12 distinct proteins (Table 1)]. Therefore,
we refer to 248 unique protein–disease associations in our
benchmark set for proteins or diseases. Supplementary
Figures S4 and S5 show that neither the size of the
protein complex (number of proteins in the complex)
nor the number of diseases in which a protein is
involved had an impact on the performance (AUC) of
its corresponding protein complex. This suggests that
TissueRanker can identify multiple biologically meaning-
ful tissues that may cause phenotypes in different diseases,
independent of the size of the protein complex.
Finally, we compared the performance of TissueRanker
with a ranking based only on single-protein expression
analysis. Speciﬁcally, we evaluated a tissue ranking
obtained by computing each protein/tissue pair’s t-statistic
of that tissue’s expression distribution compared with the
pooled distribution across all other tissues (see ‘Materials
and Methods’ section). This ranking (Figure 2B), again
compared with the gold standard, also demonstrated
that TissueRanker produced a more accurate tissue
ranking based on coordinated expression within a
protein complex (AUC=0.78) than a simpler ranking
based only on per-protein tissue-speciﬁc expression
patterns (AUC=0.59). To evaluate the performance of
TissueRanker, we ran our approach based on randomized
input data (see ‘Materials and Methods’ section) and
observed that TissueRanker, as expected, performed
better than random expectations (AUC=0.52) (Figure
2B and Supplementary Figure S2).
Assessing tissue similarity by global gene co-expression
This analysis also permitted a novel, expression-based,
comparative genome-wide analysis of 36 human tissues
(Figure 4). Different subtissue types (e.g. brain tissues
and muscle tissues) have a clear tendency to cluster
together, signifying that similar tissue types have similar
transcriptional programs executed across the different cell
types they contain. We have used the same approach to
quantitatively evaluate our results across tissue categories,
including a distance tree for the 14 tissue categories from
our benchmark study with AUC values as described
earlier in the text (Figure 5; Supplementary Figure S1B
illustrates the corresponding heatmap). Tissues with
similar co-expression patterns (Figure 4) also, in general,
perform similarly in terms of disease predictability
(Figure 5). For example, adipose and placenta cluster
together and belong both to the top performing tissues
with AUCs of 0.91 and 0.93, whereas heart and muscle
obtained 0.71 and 0.75 as AUC values, as these tissues are
close based on their pairwise correlation.
Predictive performance within and across
protein complexes
Next, we computed AUC values for each protein com-
plex in our benchmark study separately, based on the
comparison between our predictive tissue ranking and
the gold standard ranking. Supplementary Figure S2
and Supplementary Table S5 show the resulting right-
skewed distribution of all 248 complex-speciﬁc
AUC values, demonstrating that our prediction intro-
duces far less false-positive predictions than expected by
chance.
Among the protein complexes that reached the highest
AUC values (>0.9), we identiﬁed the TGFB1, SOD1 and
the AVPR2 complexes (Supplementary Table S5). Tissues
supported both by existing literature (i.e. the gold
standard) and by consistent co-expression within the
complex could be of particular interest for biological
follow-up to better understand mechanism of disease or
potential points of therapeutic intervention. On the lower
side of the distribution, the IKBKG protein complex had
the lowest AUC value (0.62), still well above background.
Low-performing complexes were again characterized by
high variability, in particular a greater diversity of pheno-
types in which they were involved. Other examples
included PTPN22 (AUC=0.63), associated with two
diseases in our benchmark displaying diverse phenotypes
(rheumatoid arthritis, OMIM #180300, and systemic
lupus erythematosus, OMIM #152700). SDHB, FGFR2
and MUTYH (AUC=0.68, 0.67 and 0.65, respectively)
were similarly associated with diverse cancer types
and thus highly variable phenotypes (Supplementary
Table S3). These protein complexes were generally
associated with only one disease in the literature
(Supplementary Table S3), however, and true predictive
performance may be difﬁcult to estimate because of
underannotation.
Table 1. The top ranked tissues (TissueRanker versus gold standard)
for two example studies in diabetes mellitus type 2 and Leigh’s
disease
Proteins Ranking TissueRanker
Diabetes mellitus type 2 (OMIM #125853): muscle, adipose, ovary,
brain, heart and kidney tissue
ABCC8 prostatejlungjkidney
HNF4A placentajheartjprostate
IRS1 adiposejbrainjskin
LIPC placentajkidneyjblood
MAPK8IP1 placentajprostatejkidney
NEUROD1 ovaryjmusclejprostate
HNF1A placentajheartjbrain
GCK uterusjkidneyjadipose
IGF2BP2 thyroidjplacentajskin
TCF7L2 placentajkidneyjblood
IL6 placentajGIjmuscle
PPARG lungjplacentajadipose
Leigh’s disease (OMIM: #256000): Brain and muscle tissue
DLD heartjkidneyjbrain
NDUFS4 bloodjbrainjkidney
NDUFV1 bloodjuterusjkidney
SDHA uterusjbloodjGI
NDUFA2 uterusjkidneyjmuscle
This table was extracted from the larger Supplementary Table S3.
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In particular, speciﬁc evidence for other examples sug-
gested the gold standard to be substantially under-
annotated (e.g. for pleiotropic features), as for the
IKBKG protein complex. The gold standard associates
the IKBKG protein with skin and GI tissue
(Supplementary Table S3), whereas TissueRanker
identiﬁes prostate tissue as being the highest co-expressed
tissue (PCC=0.75). Overall, 35% of the interactors in the
complex were highly co-expressed (PCC> 0.8) and 70%
were moderately or highly co-expressed (PCC> 0.5) with
the IKBKG protein. This provides strong experimental
support for the prediction, also detailed in our
Discussion, despite its lack of explicit prostate annotation
using our gold standard criteria. All these examples rep-
resent only a few of the ‘best’ and the ‘worst’, however,
again with the average overall complexes performing
highly accurately (overall AUC=0.78). In general,
proteins most speciﬁc to individual diseases and
tissues, without diversity of phenotypes (such as LMNA
discussed later), proved to be best predicted as illustrated
later in the text.
Tissue ranking of genes involved in distinct phenotypes
The LMNA gene is a component of the nuclear lamina
and plays an important role in nuclear assembly, chroma-
tin organization, nuclear membrane and telomere
dynamics. The LMNA gene (and protein complex)
provided an example associated both with different
phenotypes and a large variety of affected tissues (22),
such as dilated cardiomyopathy (19,23), Charcot-Marie-
Tooth disease (20), muscular dystrophy(21) or
Hutchinson-Gilford progeria syndrome (24) (for details
please refer to Supplementary Text S1).These LMNA-
associated diseases have in common that they all show a
Figure 4. Unrooted tissue distance tree of the 36 tissues from our study based on pairwise correlation of global expression data.
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high diversity of affected tissues (mainly heart, muscle and
skin) and distinct phenotypes.
The literature-based gold standard ranked tissues for
the LMNA protein according to the disease, meaning
that muscle and heart tissues were ranked ﬁrst for cardio-
myopathy, whereas skin and muscle tissues were ranked
ﬁrst for Charcot-Marie-Tooth disease. Our TissueRanker
prediction, however, ranked the tissues for the LMNA
protein according to the coordinated expression of the
corresponding protein complex, meaning that for both
diseases, skin and heart tissues were ranked ﬁrst (which
are tissues in which patients with Charcot-Marie-Tooth
disease and cardiomyopathy develop phenotypes).
Within the set of predictions for the LMNA protein
complex, skin was the highest co-expressed tissue with
an average PCC value of 0.85. Overall, 40% of the
interactors in the complex were highly co-expressed
(PCC> 0.8) and 85% were moderately or highly co-ex-
pressed (PCC> 0.5) with the hub protein LMNA. This
may suggest not only pleiotropy of phenotype, but also
possibly tissue-speciﬁc subcomponents of the complex.
TissueRanker identiﬁed heart tissue as the second
highest co-expressed tissue with PCC value of 0.48, with
8% of the interactors as highly co-expressed (PCC> 0.8)
and 50% as moderately or highly co-expressed
(PCC> 0.5) with LMNA. Only few proteins overlapped
in their coordinated expression between skin and heart,
again indicating that both predictions may be correct,
but that subcomponents of the complex function differen-
tially across tissues (and thus diseases). Only skin and
heart tissues were signiﬁcantly more co-expressed than
other tissues in the ranking for LMNA, and the complex
shows that TissueRanker can provide distinct tissue
predictions, with some speciﬁcity for individual interactors
within complexes differing across tissues and disease
phenotypes.
Tissue ranking for polygenic diseases
Polygenic diseases caused by the combination of more than
only one gene [e.g. diabetes (25)] were likewise amenable to
prediction of affected tissues using this method. In our
benchmark study, 12 proteins were associated with
diabetes mellitus type 2 (see Table 1 and Supplementary
Table S3). Diabetes affects mainly pancreas, muscle,
adipose, ovary, brain, heart and kidney tissue (26–31).
Our gold standard provided a ranking, with kidney and
adipose tissue ranked on top (see Supplementary Table
S3). Our TissueRanker predictions not only conﬁrmed
the gold standard tissues (kidney and adipose tissues),
but also detected other affected tissues that play a role in
diabetes that were not detected by the gold standard, such
as muscle, brain, ovary and heart.
Skeletal muscle
Quadriceps muscle
Atrial myocardium
Cardiac ventricle
Placenta basal plate
Adipose
Myometrium
Kidney
Prostate
Bronchial epithelia
Small intestine
Skin
Esophagus
Ovary
Bone marrow
Thyroid
Lung
Mesagnium
Smooth muscle
Eye
Lymph node
Tonsil
Bone
Blood
Thymus
Palatine tonsil
Leukocyte
Cord blood
Fetal blood
Hypothalamus
Cerebellum
Frontal cortex (Brodmann Area 4)
Frontal cortex (Brodmann Area 9)
Brain
Caudate nucleus
Hippocampal CA1
Figure 5. Unrooted tissue distance tree of the 14 tissue categories from our benchmark study based on pairwise correlation of global expression data.
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As another example, ﬁve proteins are associated with
Leigh’s disease (see Table 1 and Supplementary Table S3),
which is a neurometabolic disorder affecting mainly brain
and muscle tissue (32,33). As expected, the gold standard
ranked muscle and brain tissues as the most relevant
tissues for this disease and our TissueRanker prediction
could conﬁrm these two tissue types in three of ﬁve
proteins. However, for the DLD protein, our Tissue
Ranker prediction could identify the heart tissue as
being relevant. Indeed, Rutledge et al. (1982) have con-
ﬁrmed that hypertrophic cardiomyopathy is a frequent
associated ﬁnding in Leigh’s disease (34).
DISCUSSION
In this study, we developed TissueRanker, a predictive
approach that determines the tissue speciﬁcity of a
broad set of protein complexes based on global human
gene expression. We analysed the tissue speciﬁcity of
3590 protein complexes and the properties of complexes
speciﬁc to one or several of 36 given tissues. Our overall
performance benchmark yielded an AUC of 0.78, in
contrast with a simpler per-protein baseline of AUC=
0.59, which was particularly striking, as many of the
tested protein complexes are likely to be incompletely
annotated in our gold standard, and a random model
(AUC=0.52). We highlighted three speciﬁc biological
examples in which TissueRanker correctly predicted the
most affected disease tissue, including LEP as playing a
role in hippocampal and hypothalamus tissues, the IGF2
as being involved in smooth muscle and brain tissue, and
the inhibitor of nuclear factor kappa-light-chain-enhancer
of activated B cells IKK- as being involved in prostate
tissue, which are discussed later in additional detail.
As discussed above, previous studies aimed at
associating coordinated expression with human disease
etiology either investigated the structure of the inter
actome alone (6) or associated disease phenotypes with ex-
pression patterns across tissues (1,35–37) or within tissues
(38). Few studies had further begun to integrate both the
data types, the interactome and expression data, to analyse
the interplay between transcript expression and protein
interactions in human tissues without yet linking them to
disease etiology (5). Here, we combined all three of these
aspects–the human interactome, a large compendium of
human expression data and tissue speciﬁcity of both
expression and disease manifestation. These data together
enabled a methodology to accurately predict the tissue
speciﬁcity of protein complexes’ roles in human disease.
In associating protein complexes with human tissues
and disease, it is vital to consider the commonality and
complexity of pleiotropic effects. This is true both bio-
logically and when estimating TissueRanker’s perform-
ance based on a literature-derived gold standard.
Molecular mechanisms deregulated in disease are of
course diverse and can affect many tissues, only some of
which may be captured by current curation. The IKBKG
protein serves as an example, which was only associated
with ectodermal dysplasia (OMIM #300301) in the litera-
ture (see Supplementary Table S3). Further investigation
of the protein based on predicted associations, however,
supported an additional association with prostate cancer
and tissue as discussed below.
In addition to sparsity within the gold standard, a
similar limitation was reﬂected in the incompleteness of
this dataset’s tissue expression coverage. Although this is
the best global map of normal-tissue expression data to
date, important tissues such as liver and pancreas remain
missing. Complexes correlated (and thus highly ranked)
within missing tissues should thus again be treated care-
fully before drawing a conclusion.
A ﬁrst step we took to mitigate these effects was to
consider groups of tissue/disease associations together.
This proved beneﬁcial both for the highest ranked tissue
predictions per disease and for gold standard tissue/disease
phenotypes. TissueRanker’s underlying data source is ul-
timately expression data, subject to noise and technical
artifacts as usual in high-throughput data. Therefore, we
suggest that the user considers all top-ranked tissues, for
example, the top three tissues, or all tissues that were
ranked above a certain threshold. Further, tissue speciﬁcity
does not mean that a protein complex is always involved in
only one tissue, but instead in a selected number of tissues.
In fact, this is rather the norm, as of the 3590 protein
complexes considered in this study, only 31% are linked
to one tissue only.
Second, in addition to our global performance as-
sessment, we decomposed TissueRanker’s prediction
evaluation both into tissue-speciﬁc and protein complex-
speciﬁc AUC values. Both these indicated that the
methodology introduces far fewer incorrect predictions
than expected by chance, but more importantly emphasize
the range of performance within ‘easier’ and ‘difﬁcult’
contexts. The latter was characterized by heterogeneity
in cellular lineages and, importantly, incomplete annota-
tions in our literature-based standard. For example, the
IKBKG protein complex was the ‘worst’ performing
complex owing to an unexpected prediction of prostate
tissue involvement in disease. However, the NF-B essen-
tial modulator is also known as IKK-, which is a protein
that is encoded by the IKBKG gene and which is a subunit
of the IB kinase that activates NF-B (39). Both genes are
studied in cancer development and progression (40), and
in particular in prostate cancer (12,13), indicating a deﬁ-
ciency in our gold standard rather than in TissueRanker’s
predictions.
Together, this suggests that future studies may beneﬁt by
combining both additional literature-based gold standards
and distinct expression maps, such as those of (7) and (4),
to increase the number of tissues and replicates. This
will expand the coverage of the recent and high quality
expression map used here, which focused on biological
replicates leading to a good tissue overlap with the gold
standard, enabling an estimation of the performance of
TissueRanker. Likewise, investigation of additional
proteins not present in this gold standard may provide add-
itional insight. For example, IGF2 is a hub protein inter-
acting with nine other proteins in a protein complex deﬁned
by the InWeb network (see Figure 6). With no information
provided in the gold standard itself, we predicted IGF2 as a
highly coordinated expressed hub protein for smooth
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muscle and brain tissue (see Figure 6 and Supplementary
Table S4), matching the ﬁnding of previous studies, high-
lighting IGF2 central roles in muscle differentiation and
cerebellum morphology (10,11).
A ﬁnal important example is the LEP gene that
was concordantly expressed in the palatine tonsile,
hippocampal and hypothalamus tissues (see
Supplementary Table S4). Leptin is principally secreted
by white adipocytes, and plays a major role in the regula-
tion of body weight. It signals nutritional status to speciﬁc
hypothalamic nuclei to inhibit food intake or regulate
energy expenditure to maintain constancy of the adipose
mass. Therefore, LEP has mostly been studied in the
context of fat tissue. The signaling role to the hypothal-
amus directly explains why the protein network around
LEP is tightly regulated in that tissue. Sensory mechan-
isms of the mouth cavity are often overlooked when it
comes to studies of food uptake and metabolism.
Besides its muscle function, the tongue also has a
sensory mechanism, which was suggested to play a direct
role in modulating energy intake (41). The palatine tonsils,
present in the back of the throat, function immunologic-
ally and provide additional sensory input to the glosso-
pharyngeal nerve. No further literature is available on the
regulation of LEP in the tonsils, but our ﬁndings would
suggest further studies of LEP signaling in the oropharynx
and locally within the central nervous system (42). In add-
ition to food uptake regulation, it is emerging that LEP
also regulates diverse aspects of hippocampal synaptic
function that are thought to underlie learning and
memory processes (8). Leptin-insensitive rodents display
deﬁcits in hippocampal long-term potentiation, long-term
depression (9) and have impairments in spatial learning
and memory tasks (43). Finally, in broader human
disease, dysfunctions in the LEP system have recently
been linked to neurodegenerative disorders such as
Alzheimer’s disease, and therefore, LEP has been sug-
gested as a novel therapeutic target in Alzheimer’s
disease (8).
In conclusion, we have presented new methods for the
problem of detecting and quantifying genome-wide differ-
ences in the function of protein complexes among tissue
types in human diseases. Importantly, this approach does
not rely on disease literature or prior curation to establish
tissue rankings, but works in a de novo manner to deﬁne
these from gene expression data in normal tissues. The
method is therefore expandable to any number of tissues
when large-scale data from additional experiments are
produced. At the same time, the method is well suited
for the study and discovery of novel pleiotropic and
multi-tissue roles of gene products. The human genome
is relatively gene-poor, and it is likely that many pleio-
tropic effects still await discovery. Many of these effects
might be hard to identify in a hypothesis-driven manner,
and integration of high-throughput data, as in Tissue
Ranker, may represent a more efﬁcient approach going
forward. The tissue-based target predictions can obviously
go on to be further reﬁned to more ﬁne-grained, cell-type-
speciﬁc phenotypes as increasingly detailed single cell
expression data continue to become available.
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